Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial

BACKGROUND: Glucose variability has been associated with cardiovascular outcomes in type 2 diabetes, however, the interplay between glucose variability, empagliflozin and cardiovascular death has not been explored. In the EMPA-REG OUTCOME trial, empagliflozin reduced the risk of cardiovascular death...

Descripción completa

Detalles Bibliográficos
Autores principales: Ceriello, Antonio, Ofstad, Anne Pernille, Zwiener, Isabella, Kaspers, Stefan, George, Jyothis, Nicolucci, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556977/
https://www.ncbi.nlm.nih.gov/pubmed/33050931
http://dx.doi.org/10.1186/s12933-020-01147-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556977/
https://www.ncbi.nlm.nih.gov/pubmed/33050931
http://dx.doi.org/10.1186/s12933-020-01147-9

Ejemplares similares